Back to Search
Start Over
Mirati Therapeutics gets EMA Committeeas positive opinion for Krazati as targeted treatment option for patients with advanced NSCLC with a KRASG12C mutation
- Source :
- PharmaBiz. November 13, 2023
- Publication Year :
- 2023
-
Abstract
- Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced that following a re-examination procedure, the company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.772643575